Case Study:
Understand How to Impact Patient Adherence Using Artificial Intelligence.
AI Provides Previously Unseen Insights to Increase Adherence to Medication
There are so many causes of non-adherence, but these differ depending on the therapy area, beliefs, culture and more. So how can you understand the causes of non-adherence for your brand and your market – from real world data and not doing more market research? You already have social listening data, call center data, market research data and a whole lot more. All of this can be analyzed using Artificial Intelligence to help you identify nuances that you had not seen previously.
The Client Problem
The pharma company had a challenge with adherence dropping off for their brand after 3 months. They had results of the market research but implementing the recommendations had not resulted in markedly better adherence performance. The market research team wanted to see if AI could analyze their existing data alongside other real-world data.
The Solution
They had a wealth of market research data, social listening data, call center data and more. All of the data was put into a proprietary platform which uses Natural Language Processing alongside Machine Learning to combine the data sources, including the social listening data, and analyze it to uncover nuances that were previously not picked up. [Note: Find out whose proprietary platform in the Eularis membership – it was not ours!]
The Outcome
The client was able to get numerous insights into the different causes of non-adherence that had not been previously uncovered with the market research alone approach. This led them into being able to design interventions that had a positive impact on increasing adherence to their medication.
To achieve these kinds of results, join Eularis membership today.
Latest News
Read our latest blogs here.
How to Overcome AI Resistance and Build an AI-Ready Workforce
In 2026, 81% of physicians reported using AI for work, more than double the 38% the American Medical Association recorded in 2023. Yet AI adoption
Nobody Has Banned AI in HTA Submissions. Everybody Has Made You Answerable for It.
What NICE, CDA-AMC and the new EU JCA principles now expect the moment AI touches your evidence, and the questions nobody has answered yet On
The Vendor You Evaluated Last Year Is Not the Product You Have Now Licensed
Somewhere in your organisation, there is a slide deck from twelve months ago. It has a scorecard on it. Green, amber, a few reds that